Bevacizumab Biosimilar Market By Product Type ( 100 mg, 400 mg ), By Application ( Colorectal cancer, Lung cancer, Breast cancer, Renal cancers, Brain cancers ), Industry Trends, Estimation & Forecast, 2017 - 2025

  • Published On: Apr, 2018
  • Category: Healthcare
  • Pages: 168
Bevacizumab Biosimilar Market is expected to grow with a CAGR of xx% during the forecast period of 2018 to 2025.

Market Overview:

Bevacizumab Biosimilar is an improvised monoclonal antibody which is capable of impeding angiogenesis, by blocking the action of vascular endothelial growth factor. Bevacizumab hence, hinders the growth of new blood vessels in tumours. This drug is prescribed for the treatment of various cancers such as lung cancer, breast cancer, glioblastoma, kidney cancer and ovarian cancer. A constant rise in the number of cases of breast cancer as well as lung cancer has developed a serious demand for advanced drugs like bevacizumab all around the world. As per the data revealed by American Cancer Society, breast cancer is the most common cancer diagnosed among U.S. women, with about 252,710 new cases expected to be diagnosed in 2017. This depicts that there is a strong patient base which is present to be targeted by the major drug manufacturers. However, serious side effects such as nose bleeding, rashes, blood pressure hike, gastrointestinal perforation, blood clots and many more might act as a major challenge to the market growth. In addition to this the adoption of other types of drugs such as proto-oncogene and DLBC lymphoma drug might act as an impeding factor for the growth of the very market. The report provides detailed qualitative and quantitative analysis of the Bevacizumab Biosimilar Market. Market size and forecast in terms of value and volume has been provided for the period - (2017 - 2025), for the segments namely product type and application in each of the major regions.

Bevacizumab Biosimilar Market Segmentation

By Product Type • 100 mg • 400 mg By Application • Colorectal cancer • Lung cancer • Breast cancer • Renal cancers • Brain cancers By Geography • North America o U.S. o Canada o Mexico • Europe o U.K. o France o Germany o Italy o Spain o Rest of Europe • Asia-Pacific o China o Japan o India o Korea o Rest of APAC • South America o Brazil o Rest of South America • Rest of the World o Middle East o Africa

CHAPTER 1. INTRODUCTION 1.1. RESEARCH METHODOLOGY 1.1.1. ERC desk research 1.1.2. ERC data synthesis 1.1.3. Data validation and market feedback 1.1.4. ERC data sources CHAPTER 2. BEVACIZUMAB BIOSIMILAR MARKET OVERVIEW 2.1. BEVACIZUMAB BIOSIMILAR MARKET INTRODUCTION 2.2. GLOBAL BEVACIZUMAB BIOSIMILAR MARKET PRODUCTION AND GROWTH RATE, 2017-2025 2.2.1. Global Bevacizumab Biosimilar Production (VOLUME) and Growth Rate (%), (2017-2025) 2.3. GLOBAL BEVACIZUMAB BIOSIMILAR MARKET CAPACITY AND GROWTH RATE, 2017-2025 2.3.1. Global Bevacizumab Biosimilar Capacity (VOLUME) and Growth Rate (%), (2017-2025) 2.4. GLOBAL BEVACIZUMAB BIOSIMILAR MARKET REVENUE AND GROWTH RATE, 2017-2025 2.4.1. Global Bevacizumab Biosimilar Market Revenue (Million USD) and Growth Rate (%), (2017-2025) 2.5. GLOBAL BEVACIZUMAB BIOSIMILAR MARKET CONSUMPTION AND GROWTH RATE, 2017-2025 2.5.1. Global Bevacizumab Biosimilar Consumption (VOLUME) and Growth Rate (%), (2017-2025) 2.6. GLOBAL BEVACIZUMAB BIOSIMILAR MARKET PRICE TREND, 2017-2025 2.6.1. Global Bevacizumab Biosimilar Market Price Trend and Growth Rate (%), (2017-2025) CHAPTER 3. GLOBAL BEVACIZUMAB BIOSIMILAR MARKET BY TYPE, 2017-2025 3.1. 100 MG 3.2. 400 MG 3.3. GLOBAL BEVACIZUMAB BIOSIMILAR MARKET REVENUE BY TYPE, 2017-2025 3.3.1. Global Bevacizumab Biosimilar Market Revenue (Million USD) and Share (%) By Type, 2017-2025 3.3.2. 100 mg Market Revenue and Growth Rate, 2017-2025 3.3.3. 400 mg Market Revenue and Growth Rate, 2017-2025 3.4. GLOBAL BEVACIZUMAB BIOSIMILAR MARKET PRODUCTION BY TYPE, 2017-2025 3.4.1. Global Bevacizumab Biosimilar Market Production (Volume) and Share (%) By Type, 2017-2025 3.4.2. 100 mg Market Production and Growth Rate, 2017-2025 3.4.3. 400 mg Market Production and Growth Rate, 2017-2025 CHAPTER 4. GLOBAL BEVACIZUMAB BIOSIMILAR MARKET BY APPLICATION, 2017-2025 4.1. COLORECTAL CANCER 4.2. LUNG CANCER 4.3. BREAST CANCER 4.4. RENAL CANCER 4.5. BRAIN CANCER 4.6. GLOBAL BEVACIZUMAB BIOSIMILAR MARKET REVENUE BY APPLICATION, 2017-2025 4.6.1. Global Bevacizumab Biosimilar Market Revenue (Million USD) and Share (%) By Application, 2017-2025 4.6.2. Colorectal cancer Market Revenue and Growth Rate, 2017-2025 4.6.3. Lung cancer Market Revenue and Growth Rate, 2017-2025 4.6.4. Breast cancer Market Revenue and Growth Rate, 2017-2025 Note: Similar information coverage has been provided for other application segment. 4.7. GLOBAL BEVACIZUMAB BIOSIMILAR MARKET CONSUMPTION BY APPLICATION, 2017-2025 4.7.1. Global Bevacizumab Biosimilar Market Consumption (Volume) and share (%) By Application, 2017-2025 4.7.2. Colorectal cancer Market Consumption and Growth Rate, 2017-2025 4.7.3. Lung cancer Market Consumption and Growth Rate, 2017-2025 4.7.4. Breast cancer Market Consumption and Growth Rate, 2017-2025 Note: Similar information coverage has been provided for other application segment. CHAPTER 5. GLOBAL BEVACIZUMAB BIOSIMILAR MARKET BY REGION, 2017-2025 5.1. NORTH AMERICA 5.1.1. U.S. 5.1.2. Canada 5.1.3. Mexico 5.2. EUROPE 5.2.1. U.K. 5.2.2. France 5.2.3. Germany 5.2.4. Italy 5.2.5. Spain 5.2.6. Rest of Europe 5.3. ASIA PACIFIC 5.3.1. China 5.3.2. Japan 5.3.3. India 5.3.4. Korea 5.3.5. Rest of APAC 5.4. SOUTH AMERICA 5.4.1. Brazil 5.4.2. Rest of South America 5.5. REST OF THE WORLD 5.5.1. Middle East 5.5.2. Africa 5.6. GLOBAL BEVACIZUMAB BIOSIMILAR MARKET REVENUE BY REGION, 2017-2025 5.6.1. Global Bevacizumab Biosimilar Market Revenue (Million USD) and Share (%) By Region, 2017-2025 5.6.2. North America Market Revenue and Growth Rate, 2017-2025 5.6.3. Europe Market Revenue and Growth Rate, 2017-2025 5.6.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025 5.6.5. South America Market Revenue and Growth Rate, 2017-2025 5.6.6. Rest of the World Market Revenue and Growth Rate, 2017-2025 CHAPTER 6. GLOBAL BEVACIZUMAB BIOSIMILAR MARKET PRODUCTION AND CONSUMPTION ANALYSIS BY REGION, 2017-2025 6.1. GLOBAL BEVACIZUMAB BIOSIMILAR MARKET PRODUCTION ANALYSIS BY REGION, 2017-2025 6.1.1. Global Bevacizumab Biosimilar Market Production (Volume) and Share (%) By Region, 2017-2025 6.1.2. Global Bevacizumab Biosimilar Market Consumption (Volume) and Share (%) By Region, 2017-2025 6.1.3. North America Market Production and Consumption, 2017-2025 6.1.4. Europe Market Production and Consumption, 2017-2025 6.1.5. Asia Pacific Market Production and Consumption, 2017-2025 6.1.6. South America Market Production and Consumption, 2017-2025 6.1.7. Rest of the World Market Production and Consumption, 2017-2025 CHAPTER 7. MARKET DETERMINANTS 7.1. MARKET DRIVERS 7.2. MARKET RESTRAINTS 7.3. MARKET OPPORTUNITIES 7.4. MARKET DETERMINANTS RADAR CHART CHAPTER 8. GLOBAL BEVACIZUMAB BIOSIMILAR MARKET COMPETITION BY MANUFACTURERS 8.1. GLOBAL BEVACIZUMAB BIOSIMILAR PRODUCTION AND SHARE BY MANUFACTURERS (2017-2025) 8.1.1. Global Bevacizumab Biosimilar Production (VOLUME) and Share (%) by Manufacturers (2017-2025) 8.2. GLOBAL BEVACIZUMAB BIOSIMILAR REVENUE AND SHARE BY MANUFACTURERS (2017-2025) 8.2.1. Global Bevacizumab Biosimilar Revenue (Million USD) and Share (%) by Manufacturers (2017-2025) 8.3. BEVACIZUMAB BIOSIMILAR MARKET COMPETITIVE SITUATION AND TRENDS 8.3.1. Bevacizumab Biosimilar Market Share (%) of Top 3 Manufacturers 8.3.2. Bevacizumab Biosimilar Market Share (%) of Top 5 Manufacturers CHAPTER 9. GLOBAL BEVACIZUMAB BIOSIMILAR MANUFACTURERS ANALYSIS 9.1. PFIZER 9.1.1. Business Overview 9.1.2. Company Basic Information 9.1.3. Bevacizumab Biosimilar Product Details 9.1.4. Pfizer Bevacizumab Biosimilar Production, Revenue and Gross Margin 9.2. AMGEN 9.2.1. Business Overview 9.2.2. Company Basic Information 9.2.3. Bevacizumab Biosimilar Product Details 9.2.4. Amgen Bevacizumab Biosimilar Production, Revenue and Gross Margin 9.3. ALLERGAN 9.3.1. Business Overview 9.3.2. Company Basic Information 9.3.3. Bevacizumab Biosimilar Product Details 9.3.4. Allergan Bevacizumab Biosimilar Production, Revenue and Gross Margin 9.4. BIOCON 9.4.1. Business Overview 9.4.2. Company Basic Information 9.4.3. Bevacizumab Biosimilar Product Details 9.4.4. Biocon Bevacizumab Biosimilar Production, Revenue and Gross Margin 9.5. RELIANCE LIFESCIENCES 9.5.1. Business Overview 9.5.2. Company Basic Information 9.5.3. Bevacizumab Biosimilar Product Details 9.5.4. Reliance lifesciences Bevacizumab Biosimilar Production, Revenue and Gross Margin 9.6. BEVACIZUMAB 9.6.1. Business Overview 9.6.2. Company Basic Information 9.6.3. Bevacizumab Biosimilar Product Details 9.6.4. Bevacizumab Bevacizumab Biosimilar Production, Revenue and Gross Margin 9.7. BEACONPHARMA 9.7.1. Business Overview 9.7.2. Company Basic Information 9.7.3. Bevacizumab Biosimilar Product Details 9.7.4. Beaconpharma Bevacizumab Biosimilar Production, Revenue and Gross Margin 9.8. CELGENE CORPORATION 9.8.1. Business Overview 9.8.2. Company Basic Information 9.8.3. Bevacizumab Biosimilar Product Details 9.8.4. Celgene Corporation Bevacizumab Biosimilar Production, Revenue and Gross Margin 9.9. FUJIFILM KYOWA KIRIN BIOLOGICS 9.9.1. Business Overview 9.9.2. Company Basic Information 9.9.3. Bevacizumab Biosimilar Product Details 9.9.4. Fujifilm Kyowa Kirin Biologics Bevacizumab Biosimilar Production, Revenue and Gross Margin 9.10. HETERO DRUGS 9.10.1. Business Overview 9.10.2. Company Basic Information 9.10.3. Bevacizumab Biosimilar Product Details 9.10.4. Hetero Drugs Bevacizumab Biosimilar Production, Revenue and Gross Margin CHAPTER 10. BEVACIZUMAB BIOSIMILAR MARKET VALUE CHAIN ANALYSIS 10.1. BEVACIZUMAB BIOSIMILAR INDUSTRIAL CHAIN ANALYSIS 10.2. BEVACIZUMAB BIOSIMILAR KEY RAW MATERIALS ANALYSIS 10.2.1. Key Raw Materials 10.2.2. Price Trend of Key Raw Materials 10.2.3. Key Suppliers of Raw Materials 10.3. MARKETING CHANNEL 10.3.1. Direct Marketing 10.3.2. Indirect Marketing 10.3.3. Distributors/Traders 10.4. CONSUMER ANALYSIS 10.4.1. Consumer 1 10.4.2. Consumer 2 10.4.3. Consumer 3 10.4.4. Consumer 4

• Pfizer
• Allergan
• Amgen
• Biocon
• Reliance lifesciences
• Bevacizumab
• Beaconpharma
• Celgene Corporation
• Fujifilm Kyowa Kirin Biologics
• Hetero Drugs

Select License Type

  • $4700
  • $5600
  • $2000
  • Buy Now

Report Highlights:

Complete overview of market
Major drivers, restrain, opportunities, and challenges of the market
Market Trends and how they are boosting the market growth
Changing dynamics in the Market
Complete overview of the market
Historical, Base year, projected, and current market size in terms of value and volume
COVID-19 Impact analysis of the market
Current industry trends and developments

CLIENTS